Kronos Worldwide, Inc. produces and markets titanium dioxide pigments (TiO2) in Europe, North America, the Asia Pacific, and internationally. The company produces TiO2 in two crystalline forms, rutile and anatase to impart whiteness, brightness, opacity, and durability for various products, including paints, coatings, plastics, paper, fibers, and ceramics, as well as for various specialty products, such as inks, foods, and cosmetics and pharmaceuticals. It also produces ilmenite, a raw material used directly as a feedstock by sulfate-process TiO2 plants; iron-based chemicals, which are used as treatment and conditioning agents for industrial effluents and municipal wastewater, as well as in the manufacture of iron pigments, cement, and agricultural products; specialty chemicals for use in the formulation of pearlescent pigments, and production of electroceramic capacitors for cell phones and other electronic devices, as well as for use in natural gas pipe, and other specialty applications. In addition, the company provides technical services for its products. It sells its products under the KRONOS brand through agents and distributors to paint, plastics, decorative laminate, and paper manufacturers. The company was founded in 1916 and is headquartered in Dallas, Texas. Kronos Worldwide, Inc. is a subsidiary of Valhi, Inc.

Kronos Worldwide Inc

Akero Therapeutics ( ($AKRO) ) has provided an update. On December 9, 2025, Akero Therapeutics announced the consummation of a merger agreement tha...

Akero Therapeutics Announces Merger and Delisting Plans

The latest announcement is out from Akero Therapeutics ( ($AKRO) ). On December 2, 2025, Akero Therapeutics‘ stockholders approved the company’s ac...

Akero Therapeutics Shareholders Approve Novo Nordisk Merger

Shares in weight-loss jab firms Novo Nordisk ($NVO) and Eli Lilly ($LLY) looked a little thinner today as the World Health Organization (WHO) decla...

NVO,LLY: Shares Drop as Word Health Organization Calls for Cheaper Versions of Weight-Loss Drugs

In a report released today, Jason Zemansky from Bank of America Securities reiterated a Hold rating on Keros Therapeutics, with a price target of $...

Current Quarter	$-0.26	Next Quarter	$NA
Current Year	$-0.36	Next Year	$0.21
QoQ Growth	NaN%	YoY Growth	+158.3%
3Y EPS CAGR	-8.5%	Target Price	$6.00
Consensus	Buy	Upside	+17.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KRO	$5.11	+4.07%	572.84K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KRO	$5.11	+4.1%	572.84K
3
4
5
6

KRO

KRO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Kronos Worldwide Inc Data in Excel

Get Kronos Worldwide Inc Data in Excel